1.Postoperative lower limb ischemic necrosis following xenogeneic heart transplantation from gene-edited pigs to rhesus macaques
Xianzhi WANG ; Zhipeng REN ; Ziqiang DAI ; Rong ZHOU ; Gen ZHANG ; Jie YAN ; Yulong GUAN ; Guangyu PAN ; Xingzhuang HE ; Tingting LIU ; Shangxuan LI ; Guanzheng CUI ; Chenghong LAI ; Dengke PAN ; Dianyuan LI
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2026;33(09):1474-1481
Objective To investigate the causes and management strategies for lower limb ischemic necrosis following xenogeneic heterotopic heart transplantation from a multigene-edited pig to a rhesus monkey. Methods A xenogeneic heterotopic heart transplantation was performed on December 16, 2023, at the Institute of Experimental Animals of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, using a quintuple-gene-edited pig as the donor and a rhesus monkey as the recipient. On postoperative day (POD) 9, the recipient monkey underwent left lower limb amputation due to ischemic necrosis. Blood samples were collected at various time points after transplantation for analysis of hematologic parameters, liver and renal function, myocardial enzymes, and coagulation profiles. Ultrasound and computed tomography (CT) were used to evaluate anastomotic patency and cardiac structure. Immunological assays, including complement-dependent cytotoxicity (CDC) and IgG/IgM antibody detection, combined with clinical observations, were employed to assess rejection type and therapeutic response. Results The recipient monkey survived for 46 days after transplantation. Echocardiography demonstrated preserved biventricular systolic function in the recipient’s native heart, with left ventricular ejection fraction (LVEF) consistently exceeding 50%. In the donor pig heart, left ventricular endocardial thickening was noted on POD 9, followed by right ventricular endocardial thickening on POD 24, while LVEF remained around 35%. No hyperacute or acute rejection was detected immunologically. CDC positivity ranged between 3.4% and 5.1%, with IgG/IgM antibody binding trends consistent with CDC results. Following amputation, the recipient exhibited elevated inflammatory markers, coagulopathy, and reactive thrombocytosis, which later normalized. Immunohistochemical staining of the necrotic limb revealed arterial and venous thrombosis; however, no T-cell or B-cell infiltration was observed in vascular structures, thrombi, nerves, muscles, fascia, or skin tissues, with CD3 and CD20 staining both negative. Conclusion Limb ischemia after xenogeneic heart transplantation may be associated with lower extremity vascular thrombosis triggered by local trauma in the context of transplantation-induced inflammatory activation and coagulation dysfunction. While no clear lymphocyte-mediated rejection was observed, further studies are needed to explore the potential role of non-lymphocyte-mediated immune mechanisms.
2.Lack of Association Between DNMT3B Polymorphisms and Sporadic Parkinson's Disease in a Han Chinese Population.
Hong PAN ; Jun-Yi SHEN ; Juan-Juan DU ; Shi-Shuang CUI ; Jin LIU ; Yi-Qi LIN ; Yi-Xi HE ; Yang FU ; Chao GAO ; Gen LI ; Sheng-Di CHEN ; Jian-Fang MA
Neuroscience Bulletin 2018;34(5):867-869
3.The methylation locus and frequency pattern on p16 INK4a gene promoter CpG in epidermis of patients with psoriasis.
Min CHEN ; Pan-gen CUI ; Xu YAO ; Yuan-hua CAO ; Juan-qin GONG ; An-sheng LI ; Zhi-qiang CHEN
Chinese Journal of Medical Genetics 2007;24(6):674-676
OBJECTIVETo investigate the CpG methylation locus and frequency pattern on p16 INK4a gene promoter in epidermis of p16 INK4a methylated patients with psoriasis vulgaris.
METHODSThe DNA specimens were obtained from epidermal lesion of 50 plaque psoriatic patients. Methylation specific PCR and DNA sequencing were used to detect the frequency and locus of methylation in p16 INK4a gene promoter region.
RESULTSApproximately 50% CpG was methylated in p16 INK4a methylated patients, methylation was found in specifical locus of p16 INK4a gene promoter.
CONCLUSIONThe distinct methylation pattern is showed on the p16 INK4a gene promoter region in patients with psoriasis.
Adolescent ; Adult ; Aged ; Base Sequence ; CpG Islands ; genetics ; Cyclin-Dependent Kinase Inhibitor p16 ; genetics ; metabolism ; DNA Methylation ; genetics ; Epidermis ; metabolism ; Female ; Humans ; Male ; Middle Aged ; Molecular Sequence Data ; Polymerase Chain Reaction ; Promoter Regions, Genetic ; genetics ; Psoriasis ; genetics ; Sequence Alignment ; Tumor Suppressor Protein p14ARF ; genetics ; Young Adult
4.In vitro Antiviral activity of a berberine derivant HB-13 against herpes simplex virus
Jian-Bing WU ; Xin-Yu LI ; Lin LIN ; Pan-Gen CUI ; Jia-Run ZHENG ;
Chinese Journal of Dermatology 2003;0(11):-
Objective To evaluate the in vitro antiviral activity of HB-13,a compound derivant from berberine and its prodrug berberine,against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). Methods Vero cells were cultured in vitro and infected with HSV.Then,various concentrations of HB-13, berberine,and aciclovir were used to treat these infected cells.The cytopathic effect was observed to deter- mine the antiviral effects and cytotoxicity of HB-13 and berberine.Results For HB-13,berberine and acy- clovir,the half toxicity concentration (TC_(50)) to Vero cells was 31.99,380 and more than 800?g/mL, respectively;the average half inhibitory concentration (IC_(50)) against HSV-1 was 1.328,more than 100,and 0.443?g/mL,respectively,the treatment index (TI) against HSV-1 was 24.09,less than 3.80,and more than 1805.87,respectively;the IC_(50) against HSV-2 was 1.344,more than 100,and 0.679?g/mL,respectively,the TI against HSV-2 was 23.80,less than 3.80 and more than 1178.20,respectively.Conclusion HB-13 possesses marked antiviral activity against HSV-1 and HSV-2 in vitro,while berberine does not.
5.Weekly Cyclophosphamide Pulse Therapy Combined with Corticosteroids in the Treatment of Pemphigus
Guo-Quan JIA ; Zhi-Qiang CHEN ; He-Lian LI ; Pan-Gen CUI ; Wen-Yan XU
Acta Academiae Medicinae Sinicae 2001;23(2):173-175
Objective To investigate the better regimen of combined cyclophosphamide pulse therapy with corticosteroids in the treatment of Pemphigus. Methods Intravenous cyclophosphamide was given weekly in a dosage of 600 mg to those Pemphigus patients whose conditions couldn't be improved by corticosteroids (oral prednisone 1.2~1.5 mg/kg/d) alone. Results Ten patients with Pemphigus received weekly cyclophosphomide therapy in addition to corticosteroid. Patients conditions improved quickly, without side effects. Conclusions Cyclophosphamide weekly pulse therapy combined with corticosteroids is a good regimen in the treatment of Pemphigus.

Result Analysis
Print
Save
E-mail